Table 2.
Logistic regression analysis for the 3-month outcome.
| Parameter | Univariate Analysis | Multivariable Analysis | ||
|---|---|---|---|---|
| OR (95% CI) | P-value | OR (95% CI) | P-value | |
| Sex | 1.544 (0.672–3.550) | 0.304 | ||
| Age | 1.051 (1.008–1.095) | 0.019 | 1.150 (0.956–1.382) | 0.138 |
| BMI | 0.987 (0.879–1.108) | 0.825 | ||
| Previous stroke/TIA | 1.250 (0.571–2.736) | 0.577 | ||
| Hypertension | 1.095 (0.488–2.460) | 0.826 | ||
| Diabetes mellitus | 1.576 (0.697–3.563) | 0.275 | ||
| Cardiovascular disease | 1.248 (0.490–3.175) | 0.643 | ||
| Alcohol drinking | 0.418 (0.189–0.924) | 0.031 | 0.975 (0.048–19.774) | 0.987 |
| Current smoker | 0.912 (0.420–1.979) | 0.815 | ||
| SBP | 0.996 (0.981–1.012) | 0.635 | ||
| DBP | 0.976 (0.950–1.004) | 0.092 | ||
| NIHSS at admission | 1.275 (1.167–1.393) | <0.0001* | 1.011 (0.416–2.457) | 0.980 |
| ASTRAL at admission | 1.229 (1.143–1.322) | <0.0001* | 1.12 (0.488–2.606) | 0.779 |
| Lesion volume | 1.017 (1.009–1.025) | <0.0001* | 1.042 (1.013–1.073) | 0.005* |
| Neutrophil | 1.485 (1.239–1.781) | <0.0001* | 8.644 (1.482–50.422) | 0.017* |
| Lymphocyte, 109/L | 0.160 (0.061–0.420) | <0.0001* | 0.000 (0.000–0.043) | 0.013* |
| Neutrophil-to-lymphocyte ratio | 1.253 (1.106–1.419) | <0.0001* | 0.155 (0.030–0.798) | 0.026* |
| Platelet | 0.993 (0.986–1.000) | 0.061 | ||
| Fibrinogen | 1.320 (0.810–2.152) | 0.265 | ||
| D-dimer | 3.113 (1.681–5.762) | <0.0001* | 1.458 (0.643–3.310) | 0.367 |
| FBG | 1.054 (0.919–1.208) | 0.452 | ||
| Triglycerides | 0.549 (0.321–0.939) | 0.029* | 1.156 (0.139–9.598) | 0.893 |
| TC | 0.852 (0.607–1.194) | 0.351 | ||
| LDL-c | 0.918 (0.584–1.444) | 0.712 | ||
| HDL-c | 0.443 (0.107–1.841) | 0.263 | ||
| LDL-c-to-HDL-c ratio | 1.056 (0.651–1.714) | 0.826 | ||
| APOA | 0.142 (0.025–0.806) | 0.028* | 0.037 (0.000–25.781) | 0.323 |
| APOB | 0.880 (0.204–3.787) | 0.863 | ||
| APOA-to-APOB ratio | 0.343 (0.101–1.166) | 0.087 | ||
| Lipoprotein(a) | 1.009 (0.995–1.022) | 0.206 | ||
| Homocysteine | 0.993 (0.962–1.026) | 0.675 | ||
| Uric acid | 1.000 (0.996–1.004) | 0.954 | ||
| Interleukin-8 | 1.691 (1.331–2.149) | <0.0001* | 1.638 (1.064–2.522) | 0.025* |
| TSG-6 | 1.157 (1.249–1.975) | <0.0001* | 2.171 (1.152–4.093) | 0.017* |
| Dual antiplatelet therapy | 0.162 (0.036–0.720) | 0.017* | 0.264 (0.002–42.701) | 0.608 |
| Intravenous thrombolysis | 2.290 (0.880–5.959) | 0.090 | ||
| Endovascular therapy | 6.024 (2.111–17.192) | 0.001* | 0.404 (0.017–9.835) | 0.578 |
*P < 0.05.
OR, odds ratio; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; NIHSS, National Institute of Health Stroke Scale; ASTRAL, Acute Stroke Registry and Analysis of Lausanne; FBG, fasting blood glucose; TC total-cholesterol; LDL, low-density lipoprotein-cholesterol; HDL, high-density lipoprotein-cholesterol; APOA, apolipoprotein A; APOB, apolipoprotein B; TSG-6, tumor necrosis factor-stimulated gene-6.